Compare L3Harris Technologies Inc (LHX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs 10X Genomics Inc — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: L3Harris Technologies Inc is far larger — about 4.4× 10X Genomics Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and 10X Genomics Inc for 91 Days on average.
| LHX | TXG | |
|---|---|---|
Market Cap | $44.12B | $10.07B |
Volume | 1,202,852 | 5,657,286 |
Sector | Industrials | Health |
52-Week High | $378.48 | $97.74 |
52-Week Low | $233.63 | $11.48 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | $54.56B | $9.59B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.34% net margin and $1.61B net income in 2025. Recent $6B THAAD contract win highlights defense sector strength, though multiple law firm investigations create investor uncertainty.
Outlook remains positive with analyst consensus target of $340 (44% upside), supported by defense budget tailwinds and projected 2026 revenue growth to $22.9B. Key risks include legal investigations and debt levels, but institutional buy ratings (73.5%) signal confidence in long-term defense contracting business model.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
